Skip to main content
. 2021 Aug 12;13(8):1244. doi: 10.3390/pharmaceutics13081244

Table 2.

Summary of patient characteristics of selected models.

Model No. Age (yr) Weight (kg) Disease (cd/uc) Sex (m/f) AAA Positive (%) Albumin (g/dL) Dosage Regimen Measured Adalimumab Concentration Measured AAA
M1 NA NA NA NA NA NA
  • -

    Induction phase: 160/80 mg or 80/40 at weeks 0/2

  • -

    Maintenance phase: 40 every other week

 ELISA ELISA
M2 37 (17–61) 68 (43–109) 100/0 17/48 9 (13.8%) NA
  • -

    Induction phase: 160/80 mg or 80/40 at weeks 0/2

  • -

    Maintenance phase: 40 mg every other week

 ELISA Double-antigen ELISA
M3 13.6 (6–17) 45.2 (18–119) 100/0 105/84 83 (43.9%) 4.0 (2.4–5.3)
  • -

    Induction phase:

    • ≥40 kg: 160/80 mg at weeks 0/2

    • <40 kg: 80/40 at weeks 0/2

  • -

    Maintenance phase:

    • ≥40 kg: 40 or 20 mg every other week

    • <40 kg: 20 or 10 mg every other week

 Double-antigen ELISA Bridging ELISA
M4 38 (32–44) 65 (58–76) 100/0 35/96 17 (18%) 4.3 (4.05–4.5)
  • -

    Maintenance phase: 40 mg every week or every other week

 TNF ELISA Antigen-binding test
M5 37 (30–49) 66 (55–73) 100/0 13/28 5 (17.9%) 3.99 (3.6–4.4)
  • -

    Induction phase: 160/80 mg at weeks 0/2

  • -

    Maintenance phase: 40 mg every other week

 In-house developed TNF-coated ELISA In-house developed drug resistant AAA assay
M6 43 (32–56) 68 (56–80) 84/20 58/46 0 4.5 (4.3–4.7)
  • -

    Induction phase: 160/80 mg at weeks 0/2

  • -

    Maintenance phase: dose adjustment according to TDM

 ELISA ELISA

CD: Crohn’s disease; UC: ulcerative colitis; AAA: antibodies against adalimumab; NA = not available. The M numbers represent the models described in Table 1.